vs
Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and TRIMAS CORP (TRS). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $256.5M, roughly 1.9× TRIMAS CORP). TRIMAS CORP runs the higher net margin — 31.9% vs 6.8%, a 25.0% gap on every dollar of revenue. On growth, TRIMAS CORP posted the faster year-over-year revenue change (3.8% vs -1.7%). Over the past eight quarters, TRIMAS CORP's revenue compounded faster (3.3% CAGR vs -0.1%).
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
Trimas Corp is a diversified industrial manufacturing enterprise that designs, produces and distributes a wide portfolio of engineered products, including specialized fasteners, aerospace components, custom packaging solutions, and consumer & industrial hardware. It primarily serves aerospace, automotive, construction, consumer goods and industrial sectors, with core operations across North America and selected global markets.
MD vs TRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $493.8M | $256.5M |
| Net Profit | $33.7M | $81.7M |
| Gross Margin | — | 12.8% |
| Operating Margin | 9.9% | 5.7% |
| Net Margin | 6.8% | 31.9% |
| Revenue YoY | -1.7% | 3.8% |
| Net Profit YoY | 10.5% | 236.9% |
| EPS (diluted) | $0.40 | $2.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $256.5M | ||
| Q4 25 | $493.8M | $-140.0M | ||
| Q3 25 | $492.9M | $269.3M | ||
| Q2 25 | $468.8M | $274.8M | ||
| Q1 25 | $458.4M | $241.7M | ||
| Q4 24 | $502.4M | $-66.2M | ||
| Q3 24 | $511.2M | $229.4M | ||
| Q2 24 | $504.3M | $240.5M |
| Q1 26 | — | $81.7M | ||
| Q4 25 | $33.7M | $81.7M | ||
| Q3 25 | $71.7M | $9.3M | ||
| Q2 25 | $39.3M | $16.7M | ||
| Q1 25 | $20.7M | $12.4M | ||
| Q4 24 | $30.5M | $5.6M | ||
| Q3 24 | $19.4M | $2.5M | ||
| Q2 24 | $-153.0M | $10.9M |
| Q1 26 | — | 12.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 12.8% | ||
| Q2 25 | — | 13.8% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 15.4% | ||
| Q2 24 | — | 14.4% |
| Q1 26 | — | 5.7% | ||
| Q4 25 | 9.9% | — | ||
| Q3 25 | 13.8% | 6.2% | ||
| Q2 25 | 12.8% | 9.9% | ||
| Q1 25 | 7.0% | 9.0% | ||
| Q4 24 | 7.8% | — | ||
| Q3 24 | 6.6% | 3.6% | ||
| Q2 24 | -31.3% | 7.4% |
| Q1 26 | — | 31.9% | ||
| Q4 25 | 6.8% | -58.4% | ||
| Q3 25 | 14.5% | 3.5% | ||
| Q2 25 | 8.4% | 6.1% | ||
| Q1 25 | 4.5% | 5.1% | ||
| Q4 24 | 6.1% | -8.5% | ||
| Q3 24 | 3.8% | 1.1% | ||
| Q2 24 | -30.3% | 4.5% |
| Q1 26 | — | $2.03 | ||
| Q4 25 | $0.40 | $2.01 | ||
| Q3 25 | $0.84 | $0.23 | ||
| Q2 25 | $0.46 | $0.41 | ||
| Q1 25 | $0.24 | $0.30 | ||
| Q4 24 | $0.37 | $0.14 | ||
| Q3 24 | $0.23 | $0.06 | ||
| Q2 24 | $-1.84 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $375.2M | $30.0M |
| Total DebtLower is stronger | $570.5M | — |
| Stockholders' EquityBook value | $865.9M | $705.6M |
| Total Assets | $2.2B | $1.5B |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $30.0M | ||
| Q4 25 | $375.2M | $30.0M | ||
| Q3 25 | $340.1M | $33.6M | ||
| Q2 25 | $224.7M | $30.3M | ||
| Q1 25 | $99.0M | $32.7M | ||
| Q4 24 | $229.9M | $23.1M | ||
| Q3 24 | $103.8M | $26.9M | ||
| Q2 24 | $19.4M | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | $570.5M | $469.2M | ||
| Q3 25 | $577.2M | $407.1M | ||
| Q2 25 | $583.9M | $424.5M | ||
| Q1 25 | $590.5M | $434.2M | ||
| Q4 24 | $597.1M | $398.1M | ||
| Q3 24 | — | $409.9M | ||
| Q2 24 | — | $427.4M |
| Q1 26 | — | $705.6M | ||
| Q4 25 | $865.9M | $705.6M | ||
| Q3 25 | $890.7M | $725.0M | ||
| Q2 25 | $833.8M | $715.3M | ||
| Q1 25 | $789.2M | $686.6M | ||
| Q4 24 | $764.9M | $667.3M | ||
| Q3 24 | $732.5M | $682.8M | ||
| Q2 24 | $706.5M | $675.9M |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $2.1B | $1.4B | ||
| Q1 25 | $2.0B | $1.4B | ||
| Q4 24 | $2.2B | $1.3B | ||
| Q3 24 | $2.1B | $1.4B | ||
| Q2 24 | $2.0B | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.66× | 0.66× | ||
| Q3 25 | 0.65× | 0.56× | ||
| Q2 25 | 0.70× | 0.59× | ||
| Q1 25 | 0.75× | 0.63× | ||
| Q4 24 | 0.78× | 0.60× | ||
| Q3 24 | — | 0.60× | ||
| Q2 24 | — | 0.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $114.1M | $117.5M |
| Free Cash FlowOCF − Capex | — | $36.8M |
| FCF MarginFCF / Revenue | — | 14.4% |
| Capex IntensityCapex / Revenue | — | 18.9% |
| Cash ConversionOCF / Net Profit | 3.39× | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | — | $109.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $117.5M | ||
| Q4 25 | $114.1M | $41.5M | ||
| Q3 25 | $137.3M | $36.5M | ||
| Q2 25 | $137.2M | $30.3M | ||
| Q1 25 | $-117.5M | $9.2M | ||
| Q4 24 | $133.0M | $27.1M | ||
| Q3 24 | $91.8M | $22.0M | ||
| Q2 24 | $107.0M | $18.4M |
| Q1 26 | — | $36.8M | ||
| Q4 25 | — | $36.8M | ||
| Q3 25 | — | $22.8M | ||
| Q2 25 | — | $13.2M | ||
| Q1 25 | — | $-3.8M | ||
| Q4 24 | — | $12.1M | ||
| Q3 24 | — | $10.2M | ||
| Q2 24 | — | $7.5M |
| Q1 26 | — | 14.4% | ||
| Q4 25 | — | -26.3% | ||
| Q3 25 | — | 8.5% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | — | -1.6% | ||
| Q4 24 | — | -18.3% | ||
| Q3 24 | — | 4.4% | ||
| Q2 24 | — | 3.1% |
| Q1 26 | — | 18.9% | ||
| Q4 25 | — | -3.4% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | -22.6% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | 4.5% |
| Q1 26 | — | 1.44× | ||
| Q4 25 | 3.39× | 0.51× | ||
| Q3 25 | 1.91× | 3.92× | ||
| Q2 25 | 3.49× | 1.81× | ||
| Q1 25 | -5.66× | 0.74× | ||
| Q4 24 | 4.36× | 4.80× | ||
| Q3 24 | 4.72× | 8.71× | ||
| Q2 24 | — | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
TRS
Segment breakdown not available.
